Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles.
Published May 22, 2014 · K. Santos, M. Laranjo, A. Abrantes
European journal of medicinal chemistry
Q2 SJR score
30
Citations
0
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeaway6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles show potential as anticancer agents for triple-negative breast cancer, particularly in treating HCC1806 cells.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
[Patients' access to their medical records].
Patients' access to medical records is crucial for patient empowerment, health literacy, autonomy, self-efficacy, and satisfaction with care, and promoting awareness on this topic is essential for informed debate among stakeholders.
2013·3citations·L. Laranjo et al.·Acta medica portuguesa
Acta medica portuguesa
Chiral 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles with anti-breast cancer properties.
The enantiomer (3S)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole shows the most active anti-breast cancer activity, with a IC(50) value of 0.5
2013·50citations·M. Soares et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Targeting DNA repair in breast cancer: a clinical and translational update.
PARP inhibitors show potential as a synergistic therapy for breast cancer patients with deficient DNA repair pathways, including those with BRCA1 and BRCA2 mutations.
2010·60citations·E. Amir et al.·Cancer treatment reviews
Cancer treatment reviews
Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents.
Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles show promising anti-cancer activity against breast and colorectal cancers, with the main mechanism of action likely being the monoalkylation process.
2010·17citations·M. Soares et al.·European journal of medicinal chemistry
European journal of medicinal chemistry